Post
Amgen reports a 22% increase in Q1 2024 net revenues
Amgen’s total revenues grew in Q1 2024 to $7.4bn, displaying a 22% increase from earnings reported in the first quarter …
Angle signs AstraZeneca deal to develop prostate cancer assay
UK liquid biopsy company, Angle, has agreed a supplier agreement with AstraZeneca to develop a Parsotix-based Androgen Receptor (AR) assay for use …
FDA grants RMAT designation to Taysha’s Rett syndrome gene therapy
Taysha Gene Therapies has received a regenerative medicine advanced therapy (RMAT) designation for its gene therapy candidate TSHA-102 from the …
Lexicon plans another bid for Zynquista in type 1 diabetes
Lexicon Pharmaceuticals reaffirmed its plans to seek approval for Zynquista (sotagliflozin) as an adjunct treatment to insulin in type 1 …
ESCMID 2024: Advances in drug resistance testing
Important advances in antibiotic resistance testing methods were presented at the 34th European Society of Clinical Microbiology and Infectious Diseases …
NHS to provide Pfizer’s Voxelotor to treat sickle cell disease
The UK's National Health Service (NHS) has announced plans to offer Pfizer's Voxelotor (Oxbryta), a new treatment option for sickle …
BridgeBio Oncology Therapeutics launches with $200m funding
BridgeBio Pharma has announced the launch of BridgeBio Oncology Therapeutics (BBOT), supported by $200m of private external capital. The investment will …
Optimisation in operations: from theory to practice
How can pharmaceutical firms optimise their operations? In an industry characterised by constant flux, it is a question that logistics …
Moderna reports $1.2bn net loss in Q1 2024
Moderna experienced a substantial financial shift in the first quarter (Q1) of 2024, reporting a net loss of $1.2bn - …
ImmunityBio partners with Serum Institute for BCG vaccines
ImmunityBio has entered an exclusive worldwide agreement with the Serum Institute of India to secure a supply of Bacillus Calmette-Guerin …
Ibutamoren mesylate by Lumos Pharma for Growth Hormone Deficiency: Likelihood of Approval
Ibutamoren mesylate is under clinical development by Lumos Pharma and currently in Phase II for Growth Hormone Deficiency. According to …
ESCMID 2024: Drug resistance in fungi – a growing issue
At the 34th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global (formerly ECCMID) conference in Barcelona, Spain, drug …
Novo Nordisk aims for market domination, boasts $1.5bn obesity sales in Q1
Novo Nordisk is having a great start to the year, with the company reporting better than expected sales and profit …
Novartis acquires Mariana in $1.75bn deal to strengthen radioligand portfolio
Novartis is firming its role as the top player in the radiopharmaceutical space with the acquisition of Mariana Oncology for …
Biotechs face upward battle with recruiting patients on obesity trials
Following plans to add cohorts in an ongoing Phase II weight-loss study, Aphaia Pharma’s CSO Steffen-Sebastian Bolz says there are …